Title: COVID-19, Hydroxychloroquine and Sudden Cardiac Death: Implications for Clinical Practice in Patients with Rheumatic Diseases

Authors

Hussain Ahmed Raza[1]

Javeria Tariq[1]

Vikas Agarwal [2]

Latika Gupta[2]

Affiliations

[1]Medical College, The Aga Khan University, National Stadium Road, Karachi, 74800, Pakistan

[2]Department of Clinical Immunology and Rheumatology, SGPGIMS, Raebareli Road, Lucknow-226014, India

Corresponding Author

Dr. Latika Gupta

Assistant Professor

Department of Clinical Immunology

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Lucknow, India, 226014

drlatikagupta@gmail.com

Supplementary Table 1: Ongoing Clinical Trials

Study Title	Study design	Trial Identifier	Country	Phase	Population	Intervention Model Description	Aim
"Will Hydroxychloroquine Impede or Prevent Covid-19 (WHIP Covid-19)"	RCT	NCT04341441	USA	Phase 3	3000	The participants who meet the study entry criteria and are not on HCQ prior to study enrollment will be randomized in a 1:1:1 blinded comparison of daily or weekly oral hydroxychloroquine versus oral placebo for 8 weeks.	To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-Cov-2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo
"Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of Covid-19 (HYdILIC)"	RCT	NCT04372082	France	Phase 3	480	Participants will be randomized to receive SOC alone or SOC + hydroxychloroquine 200 mg three times a day during 10 days or SOC + association of niclosamide 2 g at J1 then 500 mg two times a day with diltiazem 60 mg three times a day during 10 days. Efficacy and tolerance of each treatments will be compared across the three treatment groups during the 28 days of follow-up.	Evaluate the efficacy of two experimental antiviral treatments, compared to standard of care (SOC), to prevent clinical worsening, hospitalization or death at day 14 in adults with documented SARS-cov-2 infection, asymptomatic or with symptoms lasting less than 8 days, and associated comorbidities without any severity criteria of the disease at inclusion
"Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With Covid-19"	RCT	NCT04358068	USA	Phase 2	20	Participants will be randomized 1:1 to receive active/placebo study treatment as follows: HCQ/Placebo 400 mg orally twice a day on Day 0 followed by 200 mg orally twice a day for 6 days, and Azithro/Placebo 500 mg once on Day 0, followed by 250 mg daily for 4 days.	To determine the Proportion of participants who died from any cause or were hospitalized
"Novel Agents for Treatment of High-risk Covid-19 Positive Patients"	RCT	NCT04374019	USA	Phase 2	240	Therapies will include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua	To determine the proportion of patients experiencing clinical deterioration.
"Efficacy of Chloroquine or Hydroxychloroquine in Covid-19 Treatment"	RCT	NCT04353336	Egypt	Phase 2 and 3	200	Interventional group: Chloroquine or Hydroxychloroquine with standard of care treatment.Control group: standard of care treatment alone	To determine the Number of patients with cure or death
"Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (Covid-19) (PROTECT)"	Open label RCT	NCT04363827	Italy	Phase 2	2300	Each index case is randomised to either Arm A: Hydroxychloroquine or Arm B: observation in a 2:1 ratio on an open label basis. Participants in the same cluster receive the same intervention.	To investigate the proportion of subjects who become symptomatic and/or swab positive in each arm within 1 month from randomization
"High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild Covid-19"	Interventional (Clinical trial)	NCT04351620	USA	Phase 1	20	1200 mg hydroxychloroquine daily will be prescribed, in divided doses	Examine the tolerability of high dose hydroxychloroquine in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications

"Hydroxychloroquine for the Treatment of Mild Covid-19 Disease (COMIHY)"	RCT	NCT04340544	Germany	Phase 3	2700	Hydroxychloroquine 600mg daily for 7 days vs placebo group	Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment
"A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of Covid-19 in Hospitalized Patients (OAHU-Covid19)"	RCT	NCT04345692	USA	Phase 3	350	Experimental: Hydroxychloroquine 400 mg 2x day by mouth on day 1, followed by 200 mg 2x day by mouth days 2-5	Clinical status at day 15
"Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed Covid-19"	RCT	NCT04336332	USA	Phase 2	160	Experimental: Arm 1: Hydroxychloroquine Sulfate + Azithromycin Experimental: Arm 2: Hydroxychloroquine Sulfate alone No Intervention: Arm 3: Placebo	Changes in patients viral load on day 3 and 6
"Hydroxychloroquine for Covid-19 (COV-HCQ)"	RCT	NCT04342221	Germany	Phase 3	220	Experimental: Hydroxychloroquine Sulfate	Determine the Effect of HCQ on in vivo viral clearance and In-hospital mortality
"Effectiveness of Hydroxychloroquine in Covid-19 Patients (Covid)"	RCT	NCT04328272	Pakistan	Phase 3	75	Experimental: Hydroxychloroquine Active Comparator: Azithromycin Placebo Comparator: Suger Tablets	Investigate the National Early Warning Score equal to zero
"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus (COSTA)"	RCT	NCT04355052	Israel	Phase 3	250	Active Comparator: A - HCQ + AZT Experimental: B - HCQ + CAM (camostat mesylate). No Intervention group	Clinical state of the patient according to NEWS scoring on day 7